Scientific corner

Granulocyte and Monocyte Apheresis for Induction of Remission in Children With New Onset Inflammatory Bowel Colitis.

Helena Rolandsdotter 1 2Michael Eberhardson 1 3Ulrika L Fagerberg 4 5Yigael Finkel 1 2 , J Pediatr Gastroenterol Nutr 2018 Jan;66(1):84-89.

Objective: The aim of the study was to analyze the effect of granulocyte and monocyte apheresis (GMA) with mesalazine for induction of remission in pediatric patients with newly onset chronic inflammatory bowel disease (IBD) colitis. Methods: Thirteen pediatric patients with newly onset extensive IBD colitis were investigated per the ECCO/ESPGHAN IBD protocol. Of these 13, 12 received 10 treatments with Adacolumn (ADA) during a median of 6.25 weeks in combination with low-to-moderate doses of mesalazine, which was continued after apheresis. A control colonoscopy was performed 12 to 16 weeks after GMA treatment. Primary outcomes were mucosal healing (Mayo endoscopic score) and histopathologic grading of biopsies. A secondary outcome was disease activity as measured by the Pediatric Ulcerative Colitis Activity Index. Results: Twelve children (6 girls) with a median age of 14.6 years and a median duration of symptoms at diagnosis of 3.2 months received all planned 10 treatment sessions with ADA. Ten of 12 patients had pancolitis and 2 of 12 extensive colitis. A final diagnosis, however, indicated ulcerative colitis in 10 children and Crohn disease in 2 children. At control colonoscopy, 8 of 12 children were in clinical remission and the Mayo endoscopic score showed significant improvement in 9 of 12 patients (P = 0.006). Complete microscopic remission, according to the Geboes score, was observed in 2 patients. Conclusions: In this small study GMA for induction of remission of newly onset pediatric IBD colitis was effective in 8 of 12 patients. Further controlled studies are warranted to confirm the efficacy of this treatment model.

Scientific corner

Granulocyte and monocyte apheresis in inflammatory bowel disease: The patients’ point of view.

Iago Rodríguez-Lago 1José Manuel Benítez 2Valle García-Sánchez 2Ana Gutiérrez 3Laura Sempere 4Daniel Ginard 5Manuel Barreiro-de Acosta 6José Luis Cabriada 7 , Gastroenterol Hepatol. Aug-Sep 2018;41(7):423-431.

Granulocyte and monocyte apheresis is well tolerated and accepted by patients with IBD. Although we found no significant differences according to type of IBD or apheresis regimen, patient perception was affected by clinical effectiveness.

Contact UsFor more information

Contact Us